Voxilaprevir: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) IUPAC name Tag: nowiki added |
Ozzie10aaaa (talk | contribs) m Cleaned up using AutoEd |
||
(24 intermediate revisions by 17 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Protease inhibitor}} |
|||
{{Use dmy dates|date=January 2020}} |
|||
{{Infobox drug |
{{Infobox drug |
||
| drug_name = |
|||
⚫ | | IUPAC_name |
||
| type = |
|||
⚫ | |||
⚫ | | IUPAC_name = (1''R'',18''R'',20''R'',24''S'',27''S'',28''S'')-''N''-[(1''R'',2''R'')-2-(Difluoromethyl)-1-<nowiki>{[(</nowiki>1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0<sup>3,12</sup>.0<sup>5,10</sup>.0<sup>18,20</sup>]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide |
||
| alt = |
|||
⚫ | |||
⚫ | |||
| alt = |
|||
⚫ | |||
<!-- Clinical data --> |
<!-- Clinical data --> |
||
| pronounce |
| pronounce = |
||
| tradename |
| tradename = Vosevi (combination with [[sofosbuvir]] and [[velpatasvir]]) |
||
| Drugs.com |
| Drugs.com = |
||
| MedlinePlus |
| MedlinePlus = |
||
| licence_EU = |
|||
⚫ | |||
| licence_US = |
|||
⚫ | |||
| |
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X --> |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
||
| legal_AU_comment = |
| legal_AU_comment = |
||
Line 22: | Line 28: | ||
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V --> |
||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
||
| legal_status |
| legal_status = <!-- Free text --> |
||
<!-- Pharmacokinetic data --> |
<!-- Pharmacokinetic data --> |
||
| bioavailability |
| bioavailability = |
||
| protein_bound |
| protein_bound = |
||
| metabolism |
| metabolism = |
||
| metabolites |
| metabolites = |
||
| onset |
| onset = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| duration_of_action = |
| duration_of_action = |
||
| excretion |
| excretion = |
||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number |
| CAS_number = 1535212-07-7 |
||
| PDB_ligand = L9P |
|||
| class |
| class = |
||
| ATCvet |
| ATCvet = |
||
| ATC_prefix |
| ATC_prefix = <!-- 'none' if uncategorised --> |
||
| ATC_suffix |
| ATC_suffix = |
||
| PubChem |
| PubChem = 89921642 |
||
| DrugBank |
| DrugBank = |
||
| ChemSpiderID |
| ChemSpiderID = 44209500 |
||
| UNII |
| UNII = 0570F37359 |
||
| KEGG = D10899 |
|||
<!-- Chemical and physical data --> |
<!-- Chemical and physical data --> |
||
⚫ | |||
| chemical_formula = |
|||
⚫ | |||
| molecular_weight = |
|||
| smiles = CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C |
| smiles = CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C |
||
| StdInChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1 |
| StdInChI = 1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1 |
||
| StdInChIKey = MZBLZLWXUBZHSL-FZNJKFJKSA-N |
| StdInChIKey = MZBLZLWXUBZHSL-FZNJKFJKSA-N |
||
| density = 1.4±0.1<ref name="chemsrc">{{Cite web|url=https://www.chemsrc.com/en/cas/1535212-07-7_1287459.html|title=voxilaprevir_msds}}</ref> |
|||
| Jmol=None |
|||
}} |
}} |
||
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor that is used in combination with [[sofosbuvir]] and [[velpatasvir]]. The combination has the trade name |
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor (by [[Gilead Sciences|Gilead]]) that is used in combination with [[sofosbuvir]] and [[velpatasvir]].<ref name="Heo_2018">{{cite journal | vauthors = Heo YA, Deeks ED | title = Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C | journal = Drugs | volume = 78 | issue = 5 | pages = 577–587 | date = April 2018 | pmid = 29546556 | doi = 10.1007/s40265-018-0895-5 | s2cid = 4395880 }}</ref> The combination has the trade name [[Vosevi]] and received a positive opinion from the European [[Committee for Medicinal Products for Human Use]] in June 2017.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=[[European Medicines Agency]]|title=Summary of opinion: Vosevi|date=22 June 2017}}</ref> |
||
On 18 July 2017, Vosevi was approved by the US [[Food and Drug Administration]].<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm FDA approves Vosevi for Hepatitis C]</ref> |
|||
==References== |
==References== |
||
Line 57: | Line 67: | ||
{{RNA antivirals}} |
{{RNA antivirals}} |
||
{{Portal bar | Medicine}} |
|||
[[Category:NS3/4A protease inhibitors]] |
[[Category:NS3/4A protease inhibitors]] |
||
[[Category:Tert-butyl compounds]] |
|||
Latest revision as of 16:37, 28 January 2023
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
PDB ligand | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
Density | 1.4±0.1[1] g/cm3 |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]
On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4]
References[edit]
- ^ "voxilaprevir_msds".
- ^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556. S2CID 4395880.
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C